Hennion & Walsh Asset Management Inc. Makes New $1.24 Million Investment in Lexeo Therapeutics, Inc. $LXEO

Hennion & Walsh Asset Management Inc. bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 265,697 shares of the company’s stock, valued at approximately $1,237,000.

A number of other large investors have also recently made changes to their positions in the stock. Allworth Financial LP increased its stake in Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after buying an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Lexeo Therapeutics in the 4th quarter worth about $37,000. California State Teachers Retirement System increased its position in shares of Lexeo Therapeutics by 123.7% during the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after acquiring an additional 2,148 shares during the period. Finally, Cerity Partners LLC purchased a new position in shares of Lexeo Therapeutics during the second quarter worth approximately $50,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $4.87 on Thursday. The company has a 50-day simple moving average of $4.64 and a two-hundred day simple moving average of $5.65. Lexeo Therapeutics, Inc. has a one year low of $3.99 and a one year high of $10.99. The company has a market capitalization of $382.39 million, a PE ratio of -3.36 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). On average, equities analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the sale, the insider owned 82,194 shares of the company’s stock, valued at $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the sale, the chief executive officer directly owned 377,817 shares in the company, valued at $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 62,204 shares of company stock valued at $280,089. Corporate insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LXEO shares. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. cut their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $18.75.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.